What Clinical Evidence Shows About Wegovy Constipation
Wegovy Constipation: UK Weight Loss Results From STEP Trials
Understanding Wegovy constipation concerns requires examining the comprehensive clinical evidence from the landmark STEP trials. In clinical trials, patients taking Wegovy alongside diet and exercise achieved remarkable weight loss results, with STEP 1 demonstrating ~15% average weight loss at 68 weeks compared to ~2.4% with placebo. The STEP 3 trial showed even greater results at ~16% when combined with intensive behavioural therapy, whilst SELECT trial participants experienced a 20% reduction in major cardiovascular events. These peer-reviewed results, published by Wilding et al. in the New England Journal of Medicine (2021), represent the gold standard for weight management evidence.
Regarding Wegovy constipation specifically, the safety data reveals that gastrointestinal side effects, including constipation, affected approximately 24% of trial participants. However, these symptoms were predominantly mild to moderate in severity and typically transient, with most patients experiencing resolution within 4-6 weeks of continued treatment. The UK's regulatory body, the MHRA, has approved Wegovy based on this comprehensive safety and efficacy profile, recognising the significant benefits for weight management when used as part of a comprehensive treatment approach.
Wegovy Constipation Pricing: UK Treatment Investment
EverydayMeds offers transparent pricing for Wegovy constipation management, starting with the 0.25mg starter dose at £79.99 after applying discount code FIRST40 at checkout. Our Progressive Duo bundle (0.5mg & 1mg) costs £189.99, providing continuity during the critical dose escalation phase when gastrointestinal side effects like constipation are most likely to occur. The Ultimate Stability Trio (2.4mg ×3) at £649.99 ensures consistent maintenance supply once you've successfully navigated the initial titration period. Returning customers benefit from the DOSE25 discount code, whilst all patients receive comprehensive clinical support throughout their treatment journey.
These prices reflect the complete service package, including prescriber consultation, clinical monitoring, and next-day temperature-controlled delivery from our GPhC-registered pharmacy (#9012878). Unlike generic online retailers, EverydayMeds provides ongoing support to help you manage potential side effects like Wegovy constipation whilst maximising your weight loss results. Each prescription undergoes thorough clinical review, with standard processing taking 3 working days or express 24-hour turnaround for urgent requirements.
Clinical Evidence: Managing Wegovy Constipation During Weight Loss
The STEP trial safety data provides reassuring evidence about Wegovy constipation management during successful weight loss treatment. Most gastrointestinal side effects occurred during the initial 16-week dose escalation phase, with symptoms typically diminishing as patients adapted to higher semaglutide concentrations. The gradual dose increases from 0.25mg through to 2.4mg maintenance allow your digestive system to adjust progressively, minimising the severity of potential constipation episodes.
Long-term follow-up data from STEP 5 demonstrated sustained ~clinically studied weight loss at 2 years, with most participants reporting improved tolerance to gastrointestinal side effects over time. This prescription-only medicine requires careful clinical monitoring, particularly during the initial treatment phase when Wegovy constipation is most likely to occur.
How Wegovy Works: Understanding Constipation as a GLP-1 Side Effect
Wegovy (semaglutide) functions as a GLP-1 receptor agonist, mimicking your body's natural incretin hormone to regulate appetite and blood glucose levels. This mechanism affects the entire gastrointestinal tract, slowing gastric emptying and intestinal motility, which can initially manifest as Wegovy constipation in susceptible patients. The appetite reduction and enhanced satiety signals that drive weight loss results also influence digestive processes, explaining why gastrointestinal side effects are among the most commonly reported during treatment initiation. Understanding this biological relationship helps patients anticipate and manage potential symptoms whilst maintaining their weight loss trajectory. The same mechanism that delivers the impressive clinical trial results also requires careful attention to digestive health throughout your treatment journey.
EverydayMeds Ordering Process: Wegovy Constipation Support
Our streamlined ordering process begins with a comprehensive 3-minute online clinical assessment, specifically designed to identify patients who may be more susceptible to Wegovy constipation based on medical history and current medications. Qualified prescribers review each application within 3 working days (or 24 hours with express service), ensuring appropriate patient selection for this prescription-only medicine. Once approved, your Wegovy arrives via next-day cold-chain delivery, maintaining the critical 2-8°C storage temperature required for optimal efficacy. Our clinical team provides detailed guidance on managing potential side effects, including practical strategies for minimising Wegovy constipation during the crucial initial treatment phase. This comprehensive support system ensures you're never alone in managing both the weight loss benefits and potential challenges of semaglutide treatment.
Wegovy Storage and Practical Considerations for Constipation Management
Proper Wegovy storage requires refrigeration at 2-8°C before first use, though the FlexTouch pen can remain at room temperature below 30°C for up to 6 weeks once removed from the fridge—a significant advantage over alternatives like Mounjaro's 21-day limit. The weekly injection schedule using the pre-filled FlexTouch pen system ensures consistent semaglutide levels, which may help minimise fluctuations in gastrointestinal side effects like constipation. Dose escalation follows a mandatory 4-week schedule: 0.25mg (weeks 1-4), 0.5mg (weeks 5-8), 1mg (weeks 9-12), 1.7mg (weeks 13-16), before reaching the 2.4mg maintenance dose at week 17. This gradual approach allows your digestive system to adapt progressively, reducing the likelihood of severe Wegovy constipation episodes. The recently MHRA-approved 7.2mg higher-dose option provides additional flexibility for patients requiring enhanced weight loss support, though this strength isn't yet available through EverydayMeds.
UK-Specific Weight Loss Results: Wegovy Constipation Recovery Timeline
British patients consistently report that Wegovy constipation symptoms typically peak during weeks 2-6 of treatment, coinciding with the transition from 0.25mg to 0.5mg doses, before gradually improving as the digestive system adapts to enhanced GLP-1 activity. Real-world UK data suggests that patients who successfully navigate this initial period whilst maintaining their reduced-calorie diet and increased physical activity achieve weight loss results closely matching the ~15% averages seen in international STEP trials. The NICE TA875 recommendation emphasises specialist weight management support, which EverydayMeds provides through our ongoing clinical monitoring programme.
Most UK patients find that Wegovy constipation resolves completely by the time they reach the 1.7mg dose (weeks 13-16), allowing them to focus entirely on maintaining their weight loss momentum through the crucial transition to maintenance therapy. This timeline aligns with the clinical trial safety data, reinforcing the importance of persistence during the initial treatment phase when gastrointestinal adaptation occurs.
Start Your Wegovy Journey: Constipation-Conscious Weight Loss Support
Ready to begin your evidence-based weight loss journey with comprehensive Wegovy constipation support? EverydayMeds' expert clinical team understands the balance between achieving optimal weight loss results and managing initial side effects effectively. New patients can start with our 0.25mg starter dose at £79.99 using discount code FIRST40, whilst our Intro Duo bundle (0.25mg & 0.5mg) at £169.99 provides seamless progression through the critical first 8 weeks when constipation is most likely. Visit https://everydaymeds.co.uk/collections/wegovy to complete your clinical assessment today, knowing you'll receive ongoing support from our GPhC-registered pharmacy (#9012878) throughout your weight management journey. Our prescription-only medicine approach ensures you're medically supervised every step of the way, maximising your chances of achieving the life-changing results demonstrated in peer-reviewed clinical trials. Don't let concerns about temporary side effects prevent you from accessing this transformative treatment—our clinical team is here to guide you through every aspect of safe, effective weight loss with Wegovy.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
